insights_auto
Mengapa 6160 naik 4,36%?
Pelajari Lebih Lanjutchevron_right
6160:HKG
BeOne Medicines AG
HK$225,00
arrow_upward
+4,36%(+9,40) 1 HR
16 Okt, 16.08.14 GMT+8 · HKD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk 6160...
Pembukaan
HK$224,80
Tinggi
HK$230,20
Rendah
HK$221,80
Kapitalisasi pasar
355,76 M
Volume rata-rata
2,93 jt
Volume
4,41 jt
Rasio P/E
65,67
Harga tinggi dalam 52 minggu terakhir
HK$235,60
Harga rendah dalam 52 minggu terakhir
HK$153,00
EPS
HK$3,43
Saham beredar
1,43 M
Jumlah karyawan
12 rb
Pembukaan
HK$224,80
Tinggi
HK$230,20
Rendah
HK$221,80
Kapitalisasi pasar
355,76 M
Volume rata-rata
2,93 jt
Volume
4,41 jt
Rasio P/E
65,67
Harga tinggi dalam 52 minggu terakhir
HK$235,60
Harga rendah dalam 52 minggu terakhir
HK$153,00
EPS
HK$3,43
Saham beredar
1,43 M
Jumlah karyawan
12 rb
Artikel berita
Dari sumber web dan partner berita
ad-hoc-news.de
·
23 jam yang lalu
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Tentang BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Karyawan12 rb
Didirikan28 Okt 2010
Kantor Pusat-
Sektor-
Situsbeonemedicines.com